Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population - Phase 1 (Real-life effectiveness of Flutiform® Phase 1)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/8878
• EU PAS number:
  EUPAS4872
• Study ID:
  8878
• Official title and acronym:
  Real-life effectiveness (and cost impact) evaluation of fixed-dose combination fluticasone propionate/formoterol (Flutiform®) for the management of asthma in a routine UK primary care population - Phase 1 (Real-life effectiveness of Flutiform® Phase 1)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

Research in Real Life

Study timelines

Date when funding contract was signed

Planned: 25/07/2012

Actual: 25/07/2012

Study start date

Planned: 01/09/2012

Actual: 01/08/2013

Data analysis start date

Planned: 01/11/2013

Actual: 01/11/2013

Date of final study report

Planned: 31/01/2014

Actual: 31/01/2014

Sources of funding

Pharmaceutical company and other private sector 

Other

More details on funding

Napp Pharmaceuticals, Resesarch in Real Life

Study protocol

Initial protocol

2014_01_28 RiRL Napp Study Protocol - Realworld Evaluation of Flutiform_version2_Phase1

Regulatory

• Was the study required by a regulatory body?:
  No